“CD8+ T cells are an important prognostic and predictive biomarker for clinical outcomes in breast cancer, and our findings showing that CKM can modulate the tumor microenvironment are intriguing,” says Dr. Gandhi. “We expect that this work will pave the way for future studies to further understand and improve responses to checkpoint inhibitors in patients with this notoriously difficult-to-treat form of breast cancer.”